UNIGE document Scientific Article
previous document  unige:19144  next document
add to browser collection
Title

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

Authors
Neuhaus, J. A.
Phillips, A. N.
Babiker, A.
Cohen, C. J.
Gatell, J. M.
Girard, P. M.
Grund, B.
show hidden authors show all authors [1 - 12]
Published in The Journal of Infectious Diseases. 2008, vol. 197, no. 8, p. 1133-1144
Abstract BACKGROUND: The SMART study randomized 5,472 human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts >350 cells/microL to intermittent antiretroviral therapy (ART; the drug conservation [DC] group) versus continuous ART (the viral suppression [VS] group). In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART. METHODS: Patients who were either ART naive (n=249) or who had not been receiving ART for ≥ 6 months (n=228) were analyzed. The following clinical outcomes were assessed: (i) opportunistic disease (OD) or death from any cause (OD/death); (ii) OD (fatal or nonfatal); (iii) serious non-AIDS events (cardiovascular, renal, and hepatic disease plus non-AIDS-defining cancers) and non-OD deaths; and (iv) the composite of outcomes (ii) and (iii). RESULTS: A total of 477 participants (228 in the DC group and 249 in the VS group) were followed (mean, 18 months). For outcome (iv), 21 and 6 events occurred in the DC (7 in ART-naive participants and 14 in those who had not received ART for ≥ 6 months) and VS (2 in ART-naive participants and 4 in those who had not received ART for 6 months) groups, respectively. Hazard ratios for DC vs. VS by outcome category were as follows: outcome (i), 3.47 (95% confidence interval [CI], 1.26-9.56; p=.02); outcome (ii), 3.26 (95% CI, 1.04-10.25; p=.04); outcome (iii), 7.02 (95% CI, 1.57-31.38; p=.01); and outcome (iv), 4.19 (95% CI, 1.69-10.39; p=.002 ). CONCLUSIONS: Initiation of ART at CD4+ cell counts >350 cells/microL compared with <250 cells/microL may reduce both OD and serious non-AIDS events. These findings require validation in a large, randomized clinical trial.
Keywords AIDS-Related Opportunistic Infections/immunology/mortalityAdultAnti-HIV Agents/*administration & dosageCD4 Lymphocyte CountCohort StudiesDrug Administration ScheduleFemaleHIV/*immunologyHIV Infections/*drug therapy/immunology/mortality/virologyHumansKaplan-Meier EstimateMaleMiddle AgedTreatment Outcome
Identifiers
PMID: 18476292
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://jid.oxfordjournals.org/content/197/8/1133.full.pdf
Structures
Citation
(ISO format)
EMERY, Stéphane et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. In: The Journal of Infectious Diseases, 2008, vol. 197, n° 8, p. 1133-1144. https://archive-ouverte.unige.ch/unige:19144

107 hits

0 download

Update

Deposited on : 2012-03-27

Export document
Format :
Citation style :